CYP26B1 and colorectal cancer: CYP26B1 which was independently prognostic in a multivariate model both in the whole patient cohort and in MMR proficient tumours represents a new biomarker of colorectal cancer and CYP26B1 may represent a novel drug target for this type of tumour.